Navigation Links
Alzheimer's Therapeutics Reviewed by NeuroPerspective
Date:9/6/2012

CARDIFF, Calif., Sept. 6, 2012 /PRNewswire/ -- NI Research has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer's therapeutics. The focus is particularly timely, given the recent release of Phase III results for bapineuzumab and solaneuzumab, which serve as a reminder of how poorly the pharma industry has allocated its resources to date, both in terms of the premature embrace of the amyloid model, and the rush into hugely expensive Phase III programs without obtaining Phase II justification.

This 46-page issue is the largest and most comprehensive issue of NeuroPerspective ever produced, and includes:

1) An overview of the biology of Alzheimer's as it is currently conceptualized, albeit not yet validated.
2) A review of the many therapeutic strategies that have been employed, and that are currently under development.
3) The companies and programs that are in clinical, preclinical, and discovery stage. Over 215 therapeutic programs are covered in this review. They include variations on the secretase theme from Bristol Myers Squibb, EnVivo Pharmaceuticals, and Neurogenetic Pharmaceuticals; innovative approaches to disease progression from Merck/Alectos, Roche/reMYND, and NeuroPhage; and those with clinical data, such as EnVivo, Lundbeck, TauRx, and Prana.  
4) What is and is not clear from the sparse solanezumab results thus far disclosed, which have served as a Rorschach for those looking to have their preconceptions supported. With all due respect to the fever dreams of some Street analysts, these results are not going to be the basis for filing a NDA.
5) A sampling of novel biomarkers in development for AD, aimed at identifying markers for MCI/prodromal AD that will permit early intervention.
6) A spotlight review of AC Immune, one of the leaders in the development of antibodies for both amyloid and tau.
7) The positive results for EnVivo Pharma's EVP-6124, and the potential for alternate mechanistic approaches to effectively address Alzheimer's.

Other topics covered in NP September:
8) Reading between the line regarding Naurex's rapid-acting antidepressant, the most important neuropsychiatric development of the year.
9) 'Elan 1969-2013:' Ramifications of Elan's decision to spin-out Neotope Bioscience.
10) The status of Merck Serono's restructuring and the implications for its CNS programming.
11) News and developments from Cortex Pharmaceuticals, NeuroSearch, and more.

NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective (formerly NeuroInvestment) is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analyses of therapeutics-in-development.

A one-year subscription to NeuroPerspective is $2,300. The September issue of NeuroPerspective is available for $400 as a single-issue purchase.

NI Research also publishes NeuroLicensing, the Private CNS Company Review, and has just launched NeuroSynopsis, a monthly four-page summary of the most important highlights from NeuroPerspective. NIR also provides consulting services to the pharma industry.

Further information and online purchasing with immediate delivery are available at http://www.niresearch.com/onlinestore.html


'/>"/>
SOURCE NI Research
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Parthenon Identifies Emerging Opportunities in Targeted Payload Cancer Therapeutics
2. Global Acute Myeloid Leukemia (AML) Therapeutics Industry
3. Addisons Disease (Primary or Chronic Adrenal Insufficiency) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
4. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
5. Hepatitis B Therapeutics - Pipeline Assessment and Market Forecasts to 2019
6. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
7. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
8. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 1
9. United Therapeutics Corporation Reports Second Quarter 2012 Financial Results
10. Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
11. United Therapeutics Corporation to Announce Second Quarter 2012 Financial Results Before Market Open on Thursday, July 26, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
(Date:3/31/2016)... 31, 2016  Genomics firm Nabsys has completed a ... Barrett Bready , M.D., who returned to the company ... technical leadership team, including Chief Technology Officer, John ... Steve Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys ...
Breaking Biology News(10 mins):